Aris Persidis, Ph.D., President, Biovista

Previous articlePatent Reform Likely to Benefit Industry Giants More Than Start-Ups
Next articleFDA Green-Lights HGS and GSK’s Systemic Lupus Erythematosus Drug Benlysta